Oxford BioMedica (LSE:OXB) Change In Receivables : £28.79 Mil (TTM As of Dec. 2023)

View and export this data going back to 2001. Start your Free Trial

What is Oxford BioMedica Change In Receivables?

Oxford BioMedica's change in receivables for the quarter that ended in Dec. 2023 was £4.80 Mil. It means Oxford BioMedica's Accounts Receivable declined by £4.80 Mil from Jun. 2023 to Dec. 2023 .

Oxford BioMedica's change in receivables for the fiscal year that ended in Dec. 2023 was £28.79 Mil. It means Oxford BioMedica's Accounts Receivable declined by £28.79 Mil from Dec. 2022 to Dec. 2023 .

Oxford BioMedica's Accounts Receivable for the quarter that ended in Dec. 2023 was £8.11 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Oxford BioMedica's Days Sales Outstanding for the six months ended in Dec. 2023 was 31.86.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Oxford BioMedica's liquidation value for the six months ended in Dec. 2023 was £-58.27 Mil.

Oxford BioMedica Change In Receivables Historical Data

The historical data trend for Oxford BioMedica's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oxford BioMedica Change In Receivables Chart

Oxford BioMedica Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-4.59

-25.89

6.89

-17.88

28.79

Oxford BioMedica Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Change In Receivables	Get a 7-Day Free Trial															6.88	-26.37	8.49	23.99	4.80

Oxford BioMedica Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £28.79 Mil.

Oxford BioMedica (LSE:OXB) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Oxford BioMedica's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	8.114	/	46.478	*	91
=	31.86

2. In Ben Graham's calculation of liquidation value, Oxford BioMedica's accounts receivable are only considered to be worth 75% of book value:

Oxford BioMedica's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	103.716	-	174.508	+	0.75 * 8.114	+	0.5 * 12.872
=	-58.27

Oxford BioMedica Change In Receivables Related Terms

Thank you for viewing the detailed overview of Oxford BioMedica's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Oxford BioMedica (LSE:OXB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oxford BioMedica PLC (LSE:OXB) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

OXBDF:USA OXBl:UK OXO:Germany

Address

Windrush Court, Transport Way, Oxford, GBR, OX4 6LT

Website

https://www.oxb.com

Oxford BioMedica PLC is a player in the healthcare market in the United Kingdom. As a biopharmaceutical company, it focuses on the field of immunotherapy by managing a platform of technologies for designing gene-based medicines. The company's operating segments include the Platform segment consists of the revenue-generating bioprocessing and process development activities undertaken for third parties. Its Product segment consists of the clinical and preclinical development of in vivo and ex vivo gene and cell therapy products. The company derives the maximum revenue from the Platform segment. Its Platform includes LentiVector, LentiStable, TRiPSystem, SecNuc, Analytics, and others. Geographically, it generates the majority of its revenue from Europe.

Oxford BioMedica (LSE:OXB) Headlines

No Headlines